Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressure

Lilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted its full‑year revenue guidance by $5 billion, prompting the stock to climb roughly 9% after the announcement.

These results helped calm investor worries about the impact of Medicare’s Bridge program and the evolving pricing environment for weight‑loss drugs, with analysts noting that robust execution across the GLP‑1 portfolio is offsetting pricing pressure.

Novartis managed to navigate a turbulent quarter, delivering results that held up despite market challenges, though the report offered limited detail on specific drivers.

GSK, meanwhile, encountered heightened investor anxiety as it awaited further developments, leaving its outlook more uncertain.